Werewolf Therapeutics Financials
| HOWL Stock | USD 2.00 0.10 5.26% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.37 | 0.3531 |
|
| |||||
| Current Ratio | 11.65 | 7.1406 |
|
|
The financial analysis of Werewolf Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Werewolf Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Werewolf | Select Account or Indicator |
Understanding current and past Werewolf Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Werewolf Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Werewolf Therapeutics' assets may result in an increase in income on the income statement.
Werewolf Therapeutics Stock Summary
Werewolf Therapeutics competes with Monte Rosa, Design Therapeutics, Ikena Oncology, Stoke Therapeutics, and Edgewise Therapeutics. Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the bodys immune system for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Werewolf Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US95075A1079 |
| CUSIP | 95075A107 |
| Location | Massachusetts; U.S.A |
| Business Address | 200 Talcott Ave, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | werewolftx.com |
| Phone | 617 952 0555 |
| Currency | USD - US Dollar |
Werewolf Therapeutics Key Financial Ratios
| Return On Equity | -0.62 | ||||
| Operating Margin | (19.55) % | ||||
| Price To Sales | 25.01 X | ||||
| Revenue | 19.94 M | ||||
| Gross Profit | (37.36 M) |
Werewolf Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Werewolf Therapeutics's current stock value. Our valuation model uses many indicators to compare Werewolf Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Werewolf Therapeutics competition to find correlations between indicators driving Werewolf Therapeutics's intrinsic value. More Info.Werewolf Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Werewolf Therapeutics' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Werewolf Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Werewolf Therapeutics Systematic Risk
Werewolf Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Werewolf Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Werewolf Therapeutics correlated with the market. If Beta is less than 0 Werewolf Therapeutics generally moves in the opposite direction as compared to the market. If Werewolf Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Werewolf Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Werewolf Therapeutics is generally in the same direction as the market. If Beta > 1 Werewolf Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Werewolf Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Werewolf Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Werewolf Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Werewolf Therapeutics November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Werewolf Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Werewolf Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Werewolf Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Werewolf Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Werewolf Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.23 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 49.02 | |||
| Value At Risk | (8.75) | |||
| Potential Upside | 9.21 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.082 | Quarterly Revenue Growth (0.86) | Return On Assets (0.26) | Return On Equity (0.62) |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.